Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1900 1
1903 1
1909 1
1911 1
1916 1
1946 1
1947 3
1949 1
1951 4
1952 1
1954 1
1955 3
1957 1
1958 2
1959 3
1960 2
1964 3
1965 2
1966 3
1967 6
1968 3
1969 1
1970 3
1971 1
1972 2
1973 4
1974 1
1975 3
1976 6
1977 2
1978 5
1979 1
1980 3
1981 4
1982 1
1983 5
1984 2
1985 3
1986 5
1987 4
1988 7
1989 6
1990 8
1991 7
1992 10
1993 9
1994 7
1995 6
1996 12
1997 7
1998 13
1999 6
2000 13
2001 8
2002 8
2003 10
2004 11
2005 11
2006 19
2007 19
2008 23
2009 17
2010 32
2011 44
2012 49
2013 48
2014 56
2015 79
2016 56
2017 80
2018 64
2019 64
2020 105
2021 109
2022 65
Text availability
Article attribute
Article type
Publication date

Search Results

1,068 results
Results by year
Filters applied: . Clear all
Page 1
Immune checkpoint inhibitors in melanoma.
Carlino MS, Larkin J, Long GV. Carlino MS, et al. Among authors: larkin j. Lancet. 2021 Sep 11;398(10304):1002-1014. doi: 10.1016/S0140-6736(21)01206-X. Lancet. 2021. PMID: 34509219 Review.
Renal cell carcinoma.
Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Hsieh JJ, et al. Among authors: larkin j. Nat Rev Dis Primers. 2017 Mar 9;3:17009. doi: 10.1038/nrdp.2017.9. Nat Rev Dis Primers. 2017. PMID: 28276433 Free PMC article. Review.
Management of toxicities of immune checkpoint inhibitors.
Spain L, Diem S, Larkin J. Spain L, et al. Among authors: larkin j. Cancer Treat Rev. 2016 Mar;44:51-60. doi: 10.1016/j.ctrv.2016.02.001. Epub 2016 Feb 6. Cancer Treat Rev. 2016. PMID: 26874776 Review.
Immune checkpoint inhibitors and cardiovascular toxicity.
Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Lyon AR, et al. Among authors: larkin j. Lancet Oncol. 2018 Sep;19(9):e447-e458. doi: 10.1016/S1470-2045(18)30457-1. Lancet Oncol. 2018. PMID: 30191849 Free article. Review.
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD. Larkin J, et al. N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28. N Engl J Med. 2019. PMID: 31562797 Free article. Clinical Trial.
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Au L, Hatipoglu E, Robert de Massy M, Litchfield K, Beattie G, Rowan A, Schnidrig D, Thompson R, Byrne F, Horswell S, Fotiadis N, Hazell S, Nicol D, Shepherd STC, Fendler A, Mason R, Del Rosario L, Edmonds K, Lingard K, Sarker S, Mangwende M, Carlyle E, Attig J, Joshi K, Uddin I, Becker PD, Sunderland MW, Akarca A, Puccio I, Yang WW, Lund T, Dhillon K, Vasquez MD, Ghorani E, Xu H, Spencer C, López JI, Green A, Mahadeva U, Borg E, Mitchison M, Moore DA, Proctor I, Falzon M, Pickering L, Furness AJS, Reading JL, Salgado R, Marafioti T, Jamal-Hanjani M; PEACE Consortium, Kassiotis G, Chain B, Larkin J, Swanton C, Quezada SA, Turajlic S; TRACERx Renal Consortium. Au L, et al. Among authors: larkin j. Cancer Cell. 2021 Nov 8;39(11):1497-1518.e11. doi: 10.1016/j.ccell.2021.10.001. Epub 2021 Oct 28. Cancer Cell. 2021. PMID: 34715028 Free PMC article.
Enhancing anti-tumour efficacy with immunotherapy combinations.
Meric-Bernstam F, Larkin J, Tabernero J, Bonini C. Meric-Bernstam F, et al. Among authors: larkin j. Lancet. 2021 Mar 13;397(10278):1010-1022. doi: 10.1016/S0140-6736(20)32598-8. Epub 2020 Dec 4. Lancet. 2021. PMID: 33285141 Review.
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.
Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, Watkins TBK, Rosenthal R, Biswas D, Rowan A, Lim E, Al Bakir M, Turati V, Guerra-Assunção JA, Conde L, Furness AJS, Saini SK, Hadrup SR, Herrero J, Lee SH, Van Loo P, Enver T, Larkin J, Hellmann MD, Turajlic S, Quezada SA, McGranahan N, Swanton C. Litchfield K, et al. Among authors: larkin j. Cell. 2021 Feb 4;184(3):596-614.e14. doi: 10.1016/j.cell.2021.01.002. Epub 2021 Jan 27. Cell. 2021. PMID: 33508232 Free PMC article.
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK. Motzer RJ, et al. Among authors: larkin j. N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16. N Engl J Med. 2019. PMID: 30779531 Free PMC article. Clinical Trial.
1,068 results